- Home
- NRDS vs INBX Comparison
NRDS vs INBX Comparison
Compare NRDS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | INBX |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NRDS | INBX |
|---|---|---|
| Price | $10.25 | $65.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 130.2K |
| Earning Date | 05-05-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.42 | ★ 649.90 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $836,600,000.00 | $200,000.00 |
| Revenue This Year | $8.80 | $563.00 |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | $15.95 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $7.55 | $10.81 |
| 52 Week High | $16.24 | $94.57 |
Technical Indicators
Market Signals| Indicator | NRDS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 35.34 |
| Support Level | $10.25 | $28.54 |
| Resistance Level | $11.39 | $85.97 |
| Average True Range (ATR) | 0.52 | 4.20 |
| MACD | 0.00 | -0.60 |
| Stochastic Oscillator | 40.79 | 2.25 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.